Markets

GW Pharmaceuticals' Epidiolex Wins New FDA Approvals

GW Pharmaceuticals' (NASDAQ: GWPH) cannabidiol (CBD) drug Epidiolex has been granted Food and Drug Administration approval for a new indication. Additionally, its previous approval has been expanded to cover a wider age range of patients.

The company announced Monday morning that the FDA had approved the oral solution of Epidiolex as a treatment for seizures in patients age 1 and older suffering from tuberous sclerosis complex (TSC) -- a rare genetic disorder in which benign tumors can grow throughout the body; the disease can also cause epilepsy.

The FDA also expanded its approval of Epidiolex to treat seizures in patients afflicted with Lennox-Gastaut syndrome or Dravet syndrome, two rare forms of epilepsy. As with TSC, the drug can now be administered to patients with these conditions who are age 1 and older.

A medical professional working with cannabis extract.

Image source: Getty Images.

In 2018, Epidiolex (marketed as Epidyolex in Europe) became the first and so far only cannabidiol-derived medication to be granted approval by the FDA. GW Pharmaceuticals is a U.K.-based specialty pharmaceutical company that concentrates on developing and marketing treatments based on CBD.

"This label expansion, including the expansion of the age range in all approved indications, further demonstrates that the FDA process can continue to enable broader patient access to appropriately tested regulatory approved cannabinoid medicines," said CEO Justin Gover.

"It also provides hope for these patients and their families and is yet another important milestone for Epidiolex as a first-in-class antiepileptic drug," he added.

Investors seem to agree. In late-afternoon trading on Monday, GW Pharmaceuticals' shares were up by about 4.5%, well outpacing the gains of the broader stock market.

Here's The Marijuana Stock You've Been Waiting For
A little-known Canadian company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming.

Cannabis legalization is sweeping over North America – 11 states plus Washington, D.C., have all legalized recreational marijuana over the last few years, and full legalization came to Canada in October 2018.

And one under-the-radar Canadian company is poised to explode from this coming marijuana revolution.

Because a game-changing deal just went down between the Ontario government and this powerhouse company...and you need to hear this story today if you have even considered investing in pot stocks.

Simply click here to get the full story now.

Learn more

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More